Infecciones severas en pacientes con artritis reumatoide tratados con fármacos antagonistas del factor de necrosis tumoral alfa
DOI:
https://doi.org/10.51481/amc.v59i1.948Palabras clave:
artritis reumatoide, terapia antiTNF, infecciones severas, epidemiología, drogas antirreumáticas modificadoras de enfermedad, prevalenciaResumen
El uso de fármacos antagonistas del factor de necrosis tumoral alfa se asocia a infecciones severas en artritis reumatoide, con una alta morbi-mortalidad en la práctica clínica. No existe casuística publicada respecto al tema en nuestro país. Se pretende aportar información relacionada con la epidemiología local de las infecciones severas e identificar factores de riesgo asociados.
Descargas
Citas
Seymour HE, Worsley A, Smith JM, Thomas SHL. Anti TNFagents for rheumatoid arthritis. Br J Clin Pharmacol 2001; 51:201-208
Delgado-Vega AM, Martin J, Granados J, Anaya JM. Epidemiología genética de la artritis reumatoide ¿Qué esperar para América Latina? Biomédica 2006; 26:562-84
Carmona L, Villaverde V, Hernández-García C, Ballina J, Gabriel R, Lafon A, et al. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology 2002; 41:88–95
Goh L, Jewell T, Laversuch T, Samantha A. A systematic review of the influence of anti-TNFon infection rates in patients with rheumatoid arthritis. Rev Bras Reumatol 2013; 53:501-515.
Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DPM. Rates of serious infections, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy. Arthritis Rheum 2006; 54:2368-2376
Haroon N, Inman R. Infectious complications of biological therapy. Curr Opin Rheumatol 2009; 21:397-403
Listing J, Strangfeld A, Kary S, Rau R, Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403-3412
Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumour necrosis factor α therapy. Arthritis Rheum 2013; 48:3013-3022
Zuo JX, Braun J, Sieper J. Immunological basis for the use of TNF -blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002; 20:S34-S37
Sacca R, Cuff C, Lesslauer W, Ruddle NH. Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 in lymphotoxininduced inflammation: critical role of TNF receptor 1 signaling, J Immunol 1998; 160:485–491
Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families, N Engl J Med 1996; 334:1717–1725
Feldman M, Elliot MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-a therapy of rheumatoid arthritis. Adv Immunol 1997; 64:283–350
Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin N Am 2009; 35:183-199
Kavanaugh A, Cohen S, Cush JJ. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. J Rheumatol 2004; 31:1881-1884
van Dartel SA, Fransen J, Kievit W, Dutmer EA, Brus HLM, Houtman NM et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012; 52:1052-1057
Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70:616-623
Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, et al. Nonviral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the Safety Assesment of Biologic Therapy (SABER) Study. Ann Rheum Dis 2013; 0:1-7
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius L, et al. Time-dependent increase in risk of hospitalisation with infection among swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66:1339–1344
Wallis RS. Biologics and infections: lessons from tumor necrosis factor blocking agents. Infect Dis Clin N Am 2011; 25:895–910
St. Claire EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1451-1459
Lipsky PE, van der Heijde D, St. Clair EW, Furst DE, Breedveld FC, Kalden, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594-1602
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med. 1999; 130:478-486
den Broeder AA, Joosten LAB, Saxne T, Heinegard D, Fenner H, Miltenburg AMM et al: Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation, Ann Rheum Dis 2002; 61:311–318
Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, et al: In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short term cellular and molecular effects, J Immunol 156:1646–1653, 1996
Charles P, Elliot MJ, Davis D, Potter A, Kalden JR, Antoni C et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Inmunnol 1999; 163:1521-1528
Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L et al. Anti tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002; 41:484-489
Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard M, et al. Infections during tumour necrosis factor α blocker therapy for rheumatic disease in daily practice: a systematic retrospective study of 709 patients. Rheumatology 2007; 46:327-334
Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a metaanalisys of tumour necrosis factor antagonist. J Rheumatol 2010; 37:928-931
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti- TNF therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70:1810-1814
Patkar NM, Teng GG, Curtis JR, Saag KG. Association of infections and tuberculosis with antitumour necrosis factor alpha therapy. Curr Opin Rheumatol 2008; 20:320-326
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. AntiTNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-2285
Stenger S. Inmunological control of tuberculosis: rol of tumour necrosis factor and more. Ann Rheum Dis 2005; 64:iv24-iv28
Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial disease and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72:37-42
Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of antiTNF therapy and increased risk of infections. Drug, Healthcare and Patient Safety 2013; 5:79-99
Galloway JB, Mercer LK, Moseley A, Dixon WG, Uistianoswski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72:229-234
Inanc N, Direskeneli H. Serious infections under treatment with TNFα antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int 2006; 27:67–71
Doran MF, Crowson CS, Pond GR, O´Fallon WM, Gabriel SE. Frequency of infection in patients with heumatoid arthritis compared with controls. Arthritis
Rheum 2002; 46:2287-2293
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: update results from the British Society for Rheumatology Biologics Register with special emphasis on risk in the erdely. Rheumatology 2011; 50:124-131
Greenberg J, Reed G, Decktor D. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134–1142
Kameda H, Ueki Y, Saito K. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol, 2010;20:531–538
Takeuchi T, Tanaka Y, Kaneko Y. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol (2012) 22:327–338
Burmester G, Mariette X, Montecucco C. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732–739
Singh J, Furst D, Bharat A. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research Vol. 64, No. 5, May 2012, pp 625–639
Calabrese LH, Zein N, Vassilopoulosen D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63(Suppl II):ii18–ii24
Gonzales-Malaver F, Guzman-Vergara CM, Bello-Gualtero JM, Varela J, MesaBetancourt AM, Londoño J, et al. Latent tuberculosis infection and viral hepatitis in a Colombian cohort of patients with biological therapy. Ann Rheum Dis 2013 71:278
Nacci F, Matucci-Cerinic M. Tuberculosis and other infections in the antitumour necrosis factor-alpha (anti-TNF-α) era. Best Pract Res Clin Rheumatol.
Jun;25:375-88
Publicado
Versiones
- 2017-02-02 (2)
- 2017-02-01 (1)
Cómo citar
Número
Sección
Licencia
Derechos de autor 2017 Acta Médica Costarricense
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
